Product Name :
SMIP 004
Description:
SKP2 (S-phase kinase-associated protein 2) inhibitor. Upregulates p27 and activates the unfolded protein response (UPR) in LNCaP prostate cancer cells overexpressing SKP2. Also induces oxidative stress. Induces proteasomal degradation of cyclin D1 and acts as CDK2 inhibitor. Arrests cell cycle in G1 phase and induces apoptosis in prostate cancer cells, but not normal cells in vitro. Inhibits growth of breast and prostate cancer xenografts in mice. Also induces autophagy and reduces replication of MERS-CoV in VeroB4 cells.
CAS:
143360-00-3
Molecular Weight:
205.30
Formula:
C13H19NO
Chemical Name:
N-(4-butyl-2-methylphenyl)acetamide
Smiles :
CCCCC1=CC=C(NC(C)=O)C(C)=C1
InChiKey:
ZFVMECVBUGMWIX-UHFFFAOYSA-N
InChi :
InChI=1S/C13H19NO/c1-4-5-6-12-7-8-13(10(2)9-12)14-11(3)15/h7-9H,4-6H2,1-3H3,(H,14,15)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Muscarine} web|{Muscarine} GPCR/G Protein|{Muscarine} TGF-beta/Smad|{Muscarine} Protocol|{Muscarine} References|{Muscarine} supplier}
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
SKP2 (S-phase kinase-associated protein 2) inhibitor. Upregulates p27 and activates the unfolded protein response (UPR) in LNCaP prostate cancer cells overexpressing SKP2. Also induces oxidative stress. Induces proteasomal degradation of cyclin D1 and acts as CDK2 inhibitor. Arrests cell cycle in G1 phase and induces apoptosis in prostate cancer cells, but not normal cells in vitro. Inhibits growth of breast and prostate cancer xenografts in mice. Also induces autophagy and reduces replication of MERS-CoV in VeroB4 cells.|Product information|CAS Number: 143360-00-3|Molecular Weight: 205.30|Formula: C13H19NO|Synonym:|SMIP004|SMIP-004|Chemical Name: N-(4-butyl-2-methylphenyl)acetamide|Smiles: CCCCC1=CC=C(NC(C)=O)C(C)=C1|InChiKey: ZFVMECVBUGMWIX-UHFFFAOYSA-N|InChi: InChI=1S/C13H19NO/c1-4-5-6-12-7-8-13(10(2)9-12)14-11(3)15/h7-9H,4-6H2,1-3H3,(H,14,15)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 100 mg/mL (487.09 mM)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Roxithromycin} site|{Roxithromycin} Antibiotic|{Roxithromycin} Biological Activity|{Roxithromycin} In stock|{Roxithromycin} custom synthesis|{Roxithromycin} Cancer} |Shelf Life: ≥12 months if stored properly.PMID:27217159 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|SMIP004 decreases the levels of positive cell cycle regulators, upregulates cyclin-dependent kinase inhibitors, and results in G1 arrest, inhibition of colony formation in soft agar, and cell death.|In Vivo:|SMIP004 potently inhibits the growth of prostate and breast cancer xenografts in SCID mice.|References:|Li C, et al. SKP2 promotes breast cancer tumorigenesis and radiation tolerance through PDCD4 ubiquitination. J Exp Clin Cancer Res. 2019 Feb 13;38(1):76.Rico-Bautista E, Zhu W, Kitada S, Small Molecule-Induced Mitochondrial Disruption Directs Prostate Cancer Inhibition via UPR Signaling. Oncotarget. 2013 Jul 14.Products are for research use only. Not for human use.|
